Dorsey Wright & Associates’s Anterix ATEX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q3
– Sell
-227
Closed -$10K – 306
2020
Q2
$10K Hold
227
– – ﹤0.01% 239
2020
Q1
$10K Sell
227
-41
-15% -$1.85K ﹤0.01% 136
2019
Q4
$12K Hold
268
– – ﹤0.01% 186
2019
Q3
$10K Hold
268
– – ﹤0.01% 247
2019
Q2
$13K Buy
268
+67
+33% +$2.83K ﹤0.01% 190
2019
Q1
$7K Sell
201
-198
-50% -$7.78K ﹤0.01% 251
2018
Q4
$15K Buy
+399
New +$15.6K ﹤0.01% 185

Other funds holding ATEX

Dorsey Wright & Associates's ATEX Position: Q3 2020 in Review

Dorsey Wright & Associates sold out of Anterix (ATEX) in Q3 2020, closing a stake of 227 shares — an estimated $10K sold.

Dorsey Wright & Associates first reported a position in ATEX in Q4 2018 and held it in 7 quarters. The position peaked at $15K in Q4 2018. 96 funds tracked by Wall St. Rank hold ATEX as of Q3 2020.

  • Dorsey Wright & Associates reported no remaining Anterix position as of Q3 2020 after selling out during the quarter.
  • Dorsey Wright & Associates sold 227 Anterix shares in Q3 2020, an estimated $10K.
  • Dorsey Wright & Associates first reported a position in Anterix in Q4 2018 and held it in 7 quarters.
  • Dorsey Wright & Associates's Anterix position peaked at $15K in Q4 2018.
  • 96 funds tracked by Wall St. Rank held Anterix as of Q3 2020.

Based on Dorsey Wright & Associates's 13F filing for Q3 2020, filed 28 Oct 2020.